Cargando…

Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery

Detalles Bibliográficos
Autores principales:	Chen, Yi, Wang, Guan, Ouyang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450161/ https://www.ncbi.nlm.nih.gov/pubmed/32855394 http://dx.doi.org/10.1038/s41392-020-00291-8

Ejemplares similares

Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents
por: Li, Lin, et al.
Publicado: (2021)

A promising strategy against SARS-CoV-2: pyrimidine inhibitors synergize with nucleoside analogues
por: Min, Long, et al.
Publicado: (2022)

Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro)
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2020)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

Towards the Ideal Synthesis of Homoallylic Ketones
por: Ferrer, Sofía, et al.
Publicado: (2015)

High-throughput base editing: a promising technology for precision medicine and drug discovery
por: Sachinidis, Agapios
Publicado: (2021)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

M(pro)-targeted anti-SARS-CoV-2 inhibitor-based drugs
por: She, Zhuxin, et al.
Publicado: (2023)

mRNA vaccine shows promise in autoimmunity
por: Flemming, Alexandra
Publicado: (2021)

Targeting folliculin to selectively inhibit mTORC1: a promising strategy for treating nonalcoholic fatty liver disease
por: Ling, Yan, et al.
Publicado: (2022)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

FXR inhibition: an innovative prophylactic strategy against SARS-CoV-2 infection
por: Li, Zhe, et al.
Publicado: (2023)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

CRISPR-mediated RNA base editing: a promising strategy to rescue deafness
por: Liu, Wenyi, et al.
Publicado: (2023)

Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes
por: Di Fazio, Pietro
Publicado: (2023)

A two‐step infection model: From SARS‐CoV‐2 entry and trafficking to egress and spread
por: You, Liting, et al.
Publicado: (2023)

Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 M(pro)
por: Citarella, Andrea, et al.
Publicado: (2023)

Antigen‐dependent multistep differentiation of T follicular helper cells and its role in SARS‐CoV‐2 infection and vaccination
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Dietary reprogram of macrophages for cell competition: a promising strategy for malignant cancer control
por: Chen, Jian, et al.
Publicado: (2023)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

Facing crises in the 21st century: microfluidics approaches for antibiotic discovery
por: Matilla, Miguel A.
Publicado: (2021)

New discoveries on how DICER efficiently processes pre‐miRNA
por: Weng, Qi, et al.
Publicado: (2023)

“Armed for the future Coronavirus pandemic”: a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine
por: Kumar, Manoj, et al.
Publicado: (2021)

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Catch-as-catch-can: mRNA vaccination boosts immune responses to SARS-CoV-2 variants
por: Pawelec, Graham, et al.
Publicado: (2021)

TMPRSS2, a novel host-directed drug target against SARS-CoV-2
por: Keller, Christian, et al.
Publicado: (2022)

New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein
por: Wang, Junzhi
Publicado: (2020)

Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy
por: Peng, Xuerun, et al.
Publicado: (2021)

Discovery of highly potent SARS-CoV-2 M(pro) inhibitors based on benzoisothiazolone scaffold
por: Chen, Weixiong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_illkn0kgpos649p7hundruebsh